Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04053322
Title Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. (DOLAF)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Age Groups: adult | senior
Covered Countries FRA

Facility Status City State Zip Country Details
Institut de Cancerologie de Montpellier Recruiting Montpellier 34000 France Details
Centre Henri-Becquerel Recruiting Rouen 76000 France Details
*Shaded cells indicate that there was no data available from for the field